TY - JOUR
T1 - Human papillomavirus vaccine knowledge and hypothetical acceptance among women in Appalachia Ohio
AU - Ruffin, Mack T.
AU - Hade, Erinn M.
AU - Gorsline, Melissa R.
AU - DeGraffinreid, Cecilia R.
AU - Katz, Mira L.
AU - Kobrin, Sarah C.
AU - Paskett, Electra D.
N1 - Funding Information:
This work was supported by grant P50 CA105632 from the National Institutes of Health . This study was also supported by the Behavioral Measurement Shared Resource at The Ohio State University Comprehensive Cancer Center (grant number P30 CA016058 ), K07 CA107079 (MLK) from the National Cancer Institute , and the National Center for Research Resources ( UL1RR025755 ).
PY - 2012/8/3
Y1 - 2012/8/3
N2 - Objective: To assess hypothetical acceptance of the human papillomavirus (HPV) vaccine for themselves and a daughter age 9-12 years among Appalachia Ohio women. Methods: Women with an abnormal Pap smear and randomly selected women with a normal Pap smear from 17 clinics completed an interview in 2006-2008. Results: From 1131 original study participants, 807 (71%) completed a survey about the HPV vaccine for their daughters and themselves. Nearly half, 380 (47%), of the participants had heard of a vaccine to prevent cancer, and 362 (95%) of respondents had heard of HPV. The participants were then told that the FDA had approved a vaccine to prevent HPV. Only 379 (38%) participants identified girls ages 9-12 years as a group who should get the vaccine. After being given the official HPV vaccine recommendation statement, 252 (31%) wanted the vaccine; 198 (25%) were "not sure"; and 353 (44%) did not want the vaccine for themselves. With respect to giving the HPV vaccine to a daughter ages 9-12 years, participants responded "yes" 445 (55%); "not sure" 163 (20%); or "no" 185 (23%). Numerous reasons were provided supporting and opposing vaccine acceptance for themselves and for a daughter. Their physician's recommendation for the HPV vaccine increased vaccine acceptance to 86% for themselves and 90% for a daughter. Conclusion: Knowledge, acceptance, and barriers about the HPV vaccine vary among women living in Appalachia Ohio. Physician recommendation is a key facilitator for vaccine diffusion in this region.
AB - Objective: To assess hypothetical acceptance of the human papillomavirus (HPV) vaccine for themselves and a daughter age 9-12 years among Appalachia Ohio women. Methods: Women with an abnormal Pap smear and randomly selected women with a normal Pap smear from 17 clinics completed an interview in 2006-2008. Results: From 1131 original study participants, 807 (71%) completed a survey about the HPV vaccine for their daughters and themselves. Nearly half, 380 (47%), of the participants had heard of a vaccine to prevent cancer, and 362 (95%) of respondents had heard of HPV. The participants were then told that the FDA had approved a vaccine to prevent HPV. Only 379 (38%) participants identified girls ages 9-12 years as a group who should get the vaccine. After being given the official HPV vaccine recommendation statement, 252 (31%) wanted the vaccine; 198 (25%) were "not sure"; and 353 (44%) did not want the vaccine for themselves. With respect to giving the HPV vaccine to a daughter ages 9-12 years, participants responded "yes" 445 (55%); "not sure" 163 (20%); or "no" 185 (23%). Numerous reasons were provided supporting and opposing vaccine acceptance for themselves and for a daughter. Their physician's recommendation for the HPV vaccine increased vaccine acceptance to 86% for themselves and 90% for a daughter. Conclusion: Knowledge, acceptance, and barriers about the HPV vaccine vary among women living in Appalachia Ohio. Physician recommendation is a key facilitator for vaccine diffusion in this region.
UR - http://www.scopus.com/inward/record.url?scp=84863992669&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84863992669&partnerID=8YFLogxK
U2 - 10.1016/j.vaccine.2012.06.034
DO - 10.1016/j.vaccine.2012.06.034
M3 - Article
C2 - 22749839
AN - SCOPUS:84863992669
SN - 0264-410X
VL - 30
SP - 5349
EP - 5357
JO - Vaccine
JF - Vaccine
IS - 36
ER -
